NK cell therapy and CAR-NK
Infusions of natural killer cells from donors or cord blood, sometimes fitted with a CAR, offering an off-the-shelf alternative to CAR-T with less cytokine release.
Overview
Natural killer cells kill cancer cells without prior sensitisation and do not cause graft-versus-host disease, so donor-derived, cord-blood or iPSC-derived NK products can be made off the shelf. CAR-NK cells against CD19 produced responses in lymphoma in early trials with little cytokine release syndrome or neurotoxicity, and cytokine-induced memory-like NK cells are tested in leukaemia. Limited persistence and expansion in patients remain the central problems.
How it works
NK cells from a donor, cord blood or a pluripotent stem cell line are expanded, optionally engineered with a CAR and interleukin-15, and infused after lymphodepletion.
- Off-the-shelf manufacturing
- Low rates of cytokine release syndrome and neurotoxicity
- No graft-versus-host disease
- Poor in vivo persistence
- Repeated dosing often needed
- No approval yet
Latest papers
topQuery for this technology: (TITLE:"NK cell therapy and CAR-NK" OR ABSTRACT:"NK cell therapy and CAR-NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NK cell therapy and CAR-NK, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyGamma-delta T cell therapy
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyOrca Bio
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia.
- InstitutionPeking University People's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- TargetCD7
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.